Join

Press Releases

Delayed 3m

Fastest customizable press release feed in the world.

Signed out · 3-min delay · Sign up for real-time

  • HCA Healthcare Inc. logo
    PR··Health Care·
    HCA Announces Proposed Public Offering of Senior Notes

    HCA Healthcare, Inc. (NYSE:HCA) today announced that its wholly owned subsidiary, HCA Inc., proposes to offer senior notes, subject to market and other considerations. Actual terms of the senior notes, including maturity, interest rate and principal amount, will depend on market conditions at the time of pricing. HCA Inc. intends to use the net proceeds from this offering for general corporate purposes, which may include the repayment of outstanding borrowings under its $4.000 billion commercial paper program (which may be reborrowed from time to time), and may use a portion of the net proceeds from this offering for the redemption of all or a portion of the $1.500 billion outstanding aggre

  • ACM Research Inc. logo
    PR··Technology·
    ACM Research Ships First PECVD SiCN System for Advanced Semiconductor Applications

    FREMONT, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- ACM Research, Inc. ("ACM") (NASDAQ:ACMR), a leading supplier of wafer and panel processing solutions for semiconductor and advanced packaging applications, today announced it has shipped its first plasma-enhanced chemical vapor deposition (PECVD) silicon carbonitride (SiCN) system to a leading semiconductor manufacturer. As the latest addition to the Saturn Series of the ACM Planetary Family, this system met customer-defined process specifications in ACM's Lingang lab and has been shipped to the customer site for validation. Designed to address advanced back-end-of-line (BEOL) requirements, the system also positions ACM to serve the growi

  • ACM Research Inc. logo
    PR··Technology·
    ACM Research Announces Preliminary Unaudited Revenue and Shipments for the First Quarter 2026

    Coincides with Release of ACM Shanghai First Quarter 2026 ResultsACM Reaffirms 2026 Revenue Outlook FREMONT, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- ACM Research, Inc. ("ACM") (NASDAQ:ACMR), a leading supplier of wafer processing solutions for semiconductor and advanced wafer-level packaging applications, today announced expectations for preliminary unaudited revenue and total shipments for the first quarter of 2026. Today's release coincides with the as-scheduled release of unaudited financial results by ACM Research (Shanghai), Inc., ACM's principal operating subsidiary ("ACM Shanghai"), to the Shanghai Stock Exchange website [link to China Disclosure]. ACM will discuss its

  • VivoPower PLC logo
    PR··Utilities·
    VivoPower Targets $1.9 Million Annualized EBITDA Uplift from Enrollment of Norway Data Center into Statnett Reserve Markets Demand Response Program

    Demand Response Program Targeted to Add USD 1.9 Million in Annualized EBITDA, with No Incremental Capex or Opex Required  Full Year Annualized EBITDA Impact Expected from Fiscal Year 2027 Enrolment in Demand Response Program Complementary to AI Tenant Operations LONDON, April 27, 2026 (GLOBE NEWSWIRE) -- VivoPower PLC (NASDAQ:VIVO) ("VivoPower" or the "Company"), a leading B Corp-certified global developer and owner of powered land and data center infrastructure for AI compute applications, today announced that its 41.5 MW Mo i Rana data center in Northern Norway has prequalified 30 MW of capacity into Statnett SF's ancillary services markets, providing balancing capacity to the Nordi

  • Norwood Financial Corp. logo
    PR··Finance·
    Norwood Financial Corp announces First Quarter Financial Results

    Quarterly Highlights: Successfully closed acquisition of Presence Bancshares.Completed core system conversion April 13, 2026.Total assets $2.9 billion.Record Net Interest Income of $24.6 million.Tangible Book Value per share $22.43. HONESDALE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- Norwood Financial Corp (the "Company") (Nasdaq Global Market-NWFL) the holding company of Wayne Bank, announced results for the first quarter ended March 31, 2026. Jim Donnelly, President and Chief Executive Officer, stated, "We are pleased to announce our first quarter results as they reflect the underlying strength of our franchise and the progress we are making in a challenging operating environment. On a

  • NXP Semiconductors N.V. logo
    PR··Technology·
    NXP Announces Availability of Proxy Materials for the Annual General Meeting of Shareholders to Be Held on June 10, 2026

    EINDHOVEN, The Netherlands, April 27, 2026 (GLOBE NEWSWIRE) -- NXP Semiconductors N.V. (NASDAQ:NXPI) will hold its annual meeting of shareholders on Wednesday, June 10, 2026 at 8:30 a.m. CET at the Company's Headquarters, High Tech Campus 60, 5656 AG, Eindhoven, The Netherlands. NXP has filed its definitive proxy statement and annual report with the U.S. Securities and Exchange Commission and this proxy statement and other related meeting materials are also available at nxp.com/agm. NXP intends to use the notice and access proxy distribution method and expects to distribute the notice of internet availability of proxy materials no later than May 20, 2026. Shareholders may request paper c

  • Cheesecake Factory Incorporated logo
    PR··Consumer Discretionary·
    The Cheesecake Factory Celebrates Moms With Sweet Gift Card Offer Online

    Receive a $10 Bonus Card for every $50 in Gift Cards Purchased Online through Mother's Day The Cheesecake Factory® (NASDAQ:CAKE), known for its extensive menu, generous portions and legendary desserts, is making Mother's Day shopping sweeter and easier with a special online gift card offer: For every $50 in Gift Cards purchased online in a single transaction from Monday, April 27, 2026 through Mother's Day, Sunday, May 10, 2026, guests will receive a complimentary $10 Bonus Card redeemable May 11, 2026 through June 3, 2026*. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427648479/en/The Cheesecake Factory celebrates Mother

  • Oncolytics Biotech Inc. logo
    PR··Health Care·
    Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study

    Company to leverage strong durability and survival data in second-line and later metastatic squamous cell anal carcinoma Pivotal study expected to focus on patients in a post-standard-of-care patient population with no FDA-approved therapies SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, an investigational, systemically delivered immunotherapy that has been shown to activate innate immune-sensing pathways, today announced that a Type C meeting with the U.S. Food and Drug Administration ("FDA") has resulted in alignment on the design of a pivotal clinical st

  • Zebra Technologies Corporation logo
    PR··Industrials·
    Zebra Technologies Celebrates 10 Year Anniversary of PartnerConnect Program

    Company marks a decade of channel-first commitment, partner growth, and customer-centric innovation Zebra Technologies Corporation (NASDAQ:ZBRA), a global leader in digitizing and automating workflows to deliver intelligent operations, today is celebrating the 10th anniversary of its Zebra™ PartnerConnect program. Zebra launched the program in 2016, unifying its global channel partners under a single, comprehensive program designed to foster growth, profitability, and success for the entire ecosystem. For a decade, Zebra has demonstrated an unwavering commitment to its more than 10,000 active channel partners globally. The PartnerConnect program provides a proven model for partner advan

  • AbbVie Inc. logo
    PR··Health Care·
    AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

    Submission supported by data from Phase 3 pivotal AFFIRM study If approved, adult Crohn's disease patients will have an additional option for induction of risankizumab-rzaa which is already approved for intravenous (IV) inductionNORTH CHICAGO, Ill., April 27, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for SKYRIZI® (risankizumab-rzaa) for subcutaneous (SC) induction for the treatment of adult patients with moderately to severely active Crohn's disease (CD). "Crohn's disease is a chronic inflammatory condition that affects an estimated 1 million Americans, and its impact often reac

  • Traeger Inc. logo
    PR··Consumer Discretionary·
    Traeger Announces Reporting Date for First Quarter 2026 Financial Results

    Traeger, Inc. ("Traeger" or the "Company") (NYSE:COOK), creator and category leader of the wood pellet grill, today announced that it will release its first quarter 2026 financial results after market close on Monday, May 11, 2026. Management will host a conference call at 4:30 p.m. Eastern Time to discuss its financial results. Those who wish to participate in the call may do so by dialing (833) 461-5787 or +1 (585) 542-9983 for international callers, conference ID 832752707. To pre-register for the conference call, please visit Traeger First Quarter 2026 Earnings Conference Call. The conference call will also be webcast live at https://investors.traeger.com. For those unable to partic

  • iRhythm Holdings Inc. logo
    PR··Health Care·
    New Data Presented at HRS 2026 Show Short-Term Holter Monitoring Misses a Large Proportion of AF Recurrence Post-Ablation and Clinically Significant Arrhythmias in Pregnancy

    Real-world data presented at HRS 2026 add to the body of evidence supporting a shift away from short-duration Holter monitoring toward up to 14 days of continuous, uninterrupted monitoring with Zio® ambulatory ECG devices to reduce missed arrhythmias and provide a more complete assessment of arrhythmia burden, including in post-ablation and pregnancy populations.1-2Findings raise important considerations for post-ablation anticoagulation decisions based on prior studies such as the OCEAN trial that relied on short-duration (24–48-hour) monitoring, as these data show this approach would miss AF recurrence in 26% of patients.1 SAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdin

  • Terns Pharmaceuticals Inc. logo
    PR··Health Care·
    Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia

    FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to TERN-701, a novel, oral allosteric BCR::ABL1 inhibitor, for the treatment of adult patients with Ph+ CML in the chronic phase without the T315I mutation previously treated with two or more TKIs. "There remains an urgent need for CML treatments that offer improved efficacy, safety, and tolerability over current therapies," said Scott Harris, chief development and operations officer at Terns. "This designation from the FDA su

  • Johnson & Johnson logo
    PR··Health Care·
    FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)

    Priority Review is granted to medicines that may offer significant improvements in safety or effectiveness for serious conditions like warm autoimmune hemolytic anemia, a life-threatening disease in which pathogenic immunoglobulin G autoantibodies attach to and destroy red blood cells, leading to debilitating anemiaIMAAVY is designed to target the underlying cause of warm autoimmune hemolytic anemia by reducing circulating immunoglobulin G, including autoantibodies, while preserving critical immune functions Pivotal study showed rapid and durable hemoglobin responsea and fatigue improvementb compared to placebo in patients with warm autoimmune hemolytic anemiaSPRING HOUSE, Pa., April 27, 202

  • TransCode Therapeutics Inc. logo
    PR··Health Care·
    TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University

    BOSTON, April 27, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering RNA and immuno-oncology therapeutics for the treatment of high risk and advanced cancers, today announced the appointment of Anna Moore, PhD, as Chair of its Scientific Advisory Board and the signing of a sponsored research agreement (SRA) with Michigan State University (MSU). Dr. Moore, Associate Dean for Research Development, Director of the Precision Health Program and Professor in the Departments of Radiology and Physiology at Michigan State University, is a

  • Business First Bancshares Inc. logo
    PR··Finance·
    Business First Bancshares, Inc., Announces Financial Results for Q1 2026

    BATON ROUGE, La. , April 27, 2026 (GLOBE NEWSWIRE) -- Business First Bancshares, Inc. (NASDAQ:BFST) (Business First), parent company of b1BANK, today announced its unaudited results for the quarter ended March 31, 2026. Business First reported net income available to common shareholders of $22.2 million or $0.68 per diluted common share, an increase of $1.2 million and a decrease of $0.03, respectively, compared to the linked quarter. On a non-GAAP basis, core net income for the quarter ended March 31, 2026, which excludes certain income and expenses, was $24.0 million or $0.73 per diluted common share, an increase of $0.5 million and a decrease of $0.06 from the linked quarter. The quarte

  • Royal Bank Of Canada logo
    PR··Finance·
    RBC Wealth Management wins dual recognition for its use of AI to better empower advisors

    PWM Wealth Tech Awards recognize RBC's strategy of pairing top-tier advisors with intelligent technology to drive growth and client outcomesTORONTO, April 27, 2026 /CNW/ - RBC Wealth Management, Canada's largest full-service wealth management firm, has won two prestigious awards at the PWM Wealth Tech Awards, securing Best Private Bank for Digitally Empowering Relationship Managers in Canada and Best Private Bank for Use of Technology in Canada, for its capabilities across RBC's Canadian wealth management and private banking businesses. These awards recognize RBC's leadership in

  • NextPlat Corp logo
    PR··Telecommunications·
    NextPlat Regains Compliance with Nasdaq Bid Price Requirement

    HALLANDALE BEACH, Fla., April 27, 2026 /PRNewswire/ -- NextPlat Corp (NASDAQ:NXPL, NXPLW), NXPLW) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels worldwide, today announced that on April 27, 2026, the Company received a letter (the "Compliance Letter") from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). As a result, the matter has been closed.

  • Avient Corporation logo
    PR··Industrials·
    Avient Announces Giuseppe (Joe) Di Salvo as Chief Financial Officer

    CLEVELAND, April 27, 2026 /PRNewswire/ -- Avient Corporation (NYSE:AVNT), an innovator of materials solutions, announced today that Giuseppe (Joe) Di Salvo has been promoted and named Senior Vice President and Chief Financial Officer, effective June 1, 2026. He will succeed Jamie A. Beggs, who will be leaving Avient June 1, 2026 to pursue other opportunities. Mr. Di Salvo brings 25 years of financial experience, including nearly 15 years at Avient, with extensive experience in investor relations, accounting, financial planning and analysis, and treasury. This diverse experience

  • Sierra Bancorp logo
    PR··Finance·
    Sierra Bancorp Reports First Quarter 2026 Results

    Sierra Bancorp (NASDAQ:BSRR), parent of Bank of the Sierra, today announced its unaudited financial results for the quarter ended March 31, 2026. Sierra Bancorp reported consolidated net income of $12.5 million, or $0.96 per diluted share, for the first quarter of 2026 compared to $9.1 million, or $0.65 per diluted share, in the first quarter of 2025. Highlights for the First Quarter of 2026 (unless otherwise stated): Strong Quarterly Earnings Metrics Diluted earnings per share increased $0.31, or 47%, from the same quarter in 2025. Return on average assets improved to 1.39% compared to 1.02% for the same quarter in 2025. Return on average equity rose to 13.88% compared to 10.4